Drug manufacturers’ decades old commercial model – which initially depended on manufacturers having a plethora of “feet in the street” and ample face-to-face, in-person interactions with physicians – was in jeopardy long before the pandemic began. Covid-19 has accelerated the need for change.
The Pharma Commercial Model Was Under Stress Before Covid-19. Here’s What Needs To Change
